Sanne Weijzen

Member of The Supervisory Board

2024 - Current

Sanquin Health Solutions stands for unlocking the potential of blood and science for the benefit of patients and is responsible for managing all of Sanquin's commercial activities, including those derived from Sanquin Research. The company stimulates and facilitates the development of innovative products and services in the area of transfusion medicine, hematology, immunology and oncology. Under SHS fall Sanquin's activities in the fields of diagnostics, in vitro reagents, technology valorisation and campus development.

VP, Head of Corporate Strategy and Global Operations, member of the Executive Committee

2024

Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers.

VP, Head of Corporate Strategy and EU Operations

2021 - 2024

COO

2018 - 2021

Scenic employs a revolutionary genetics approach that can unearth a totally new kind of drug target for a great variety of diseases. We call these drug targets “disease suppressors”. Our current focus is on developing small molecules for rare genetic disorders and immuno-oncology.

Owner

2015 - 2018

CoMetis: (ad-interim) Management and Consulting in the Life Sciences CoMetis helps companies in the life science: * To support the generation of company strategy align this with company operations * To generate solid business cases and make them investor ready. * To obtain financing * To build the company or new business case * To manage the company to accomplish its mission

Ad-interim Chairman of the Supervisory Board

2013 - 2015

MicroRNA’s (miRNA’s) regulate many different cell processes and aberrant miRNA expression leads to the induction of numerous diseases, including cancer. InteRNA has generated the largest expression library, encoding 1100 different public and proprietary miRNAs, and uses this to identify their functions in several cancer-related biological processes. InteRNA has identified miRNA mimics that affect growth of tumor vessels and miRNA mimics that inhibit skin cancer growth and aims to bring these new drugs to the patient in the coming years.

Member of the Supervisory Board

2011 - 2015

Partner

2011 - 2014

AGLAIA is a Dutch venturing organization committed to creating and building biomedical companies in the field of oncology. Aglaia -through its investment funds- does not only provide the financial means, but also plays an active role in building its portfolio companies up to the level where they gain the interest from pharmaceutical and biotech companies. Aglaia BioMedical Ventures B.V. has three investment funds under management: Aglaia Oncology Fund B.V. (AOFI) and Aglaia Oncology Seed Fund B.V. (AOSF), closed in 2006. It closed its third investment fund, Aglaia Oncology Fund II B.V. (AOFII) at EUR 50M in 2014. As one of the partners at Aglaia, my responsibilities included the following: - Selection of new investment opportunities - Fundraising for AOFII: First close at EUR 50M (Sep 2014), final close targeted at EUR 60-80M. - Financial management of AOFI and AOSF (incl. fin. administration, budgeting, cash flow management) - Supervision of a selection of portfolio companies - Support portfolio companies in financing rounds - Interim management of portfolio company SomantiX (Aglaia portfolio company)

Investment Manager

2009 - 2011

As investment manager, my responsibilities included the following: - Selection of investment opportunities - Determination of business strategy of portfolio companies (early stage start-up companies) - Writing of business plans for NewCo's in which Aglaia wanted to invest - Lining up business strategy with IP strategy and project strategy - Design and control of IP strategy - IP management and coordination for 3 portfolio companies - Involvement with financing rounds of InteRNA (Aglaia portfolio company)

Business Analyst

2006 - 2009

As a business analyst, my responsibilities included the following: - Support partners by supplying business intelligence concerning possible investment opportunities. - Contribute to the generation of business plans - Perform feasibility analyses - IP management and coordination for 3 portfolio companies - Incubation and interim management of InteRNA Technologies

Post-doc Dept. of Physiological Chemistry

2002 - 2006